by Chatelain E, Ioset JR. Expert Opinion on Drug Discovery 2017, doi 10.1080/17460441.2018.1417380.
Summary: In a context of disappointing results from target-based drug discovery for Chagas disease, the authors critically evaluate the advantages and limitations of phenotypic-based approaches developed in the last 15 years, and assess their relevance and potential for improvement. They conclude that phenotypic assays have changed the disease discovery landscape and contributed to a better understanding of parasite/host interactions, and that recent examples of target resolution from phenotypic hits will uncover new opportunities for drug discovery for Chagas disease.
